Drug Profile


Alternative Names: Tazobac; Tazobactam/piperacillin; Tazobactam/piperacillin 1:8 ratio product; Tazocel; Tazocilline; Tazocin; YP-18; Zosyn

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NAEJA Pharmaceutical; Taiho Pharmaceutical
  • Developer Taiho Pharmaceutical; Toyama Chemical
  • Class Antibacterials; Carboxylic acids; Penicillins; Piperazines
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Bacterial infections; Biliary tract infections; Cholangitis; Cholecystitis; Febrile neutropenia; Intra-abdominal infections; Nosocomial pneumonia; Peritonitis; Respiratory tract infections; Sepsis; Skin and soft tissue infections; Urinary tract infections

Most Recent Events

  • 19 May 2017 Launched for Skin and soft tissue infections in Japan (IV)
  • 18 May 2017 Registered for Skin and soft tissue infections in Japan (IV)
  • 31 Dec 2016 Preregistration for Skin and soft tissue infections in Japan (IV) (Taiho Pharmaceutical pipeline, December 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top